These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 19261633)
21. Histologic grading of canine mast cell tumor: is 2 better than 3? Sabattini S; Scarpa F; Berlato D; Bettini G Vet Pathol; 2015 Jan; 52(1):70-3. PubMed ID: 24513799 [TBL] [Abstract][Full Text] [Related]
22. The value of immunohistochemical expression of BAX in formulating a prognosis for canine cutaneous mast cell tumours. Strefezzi Rde F; Kleeb SR; Xavier JG; Fukumasu H; Catão-Dias JL J Comp Pathol; 2012 May; 146(4):314-9. PubMed ID: 21899858 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs. Fulcher RP; Ludwig LL; Bergman PJ; Newman SJ; Simpson AM; Patnaik AK J Am Vet Med Assoc; 2006 Jan; 228(2):210-5. PubMed ID: 16426187 [TBL] [Abstract][Full Text] [Related]
24. Association of breed and histopathological grade in canine mast cell tumours. Mochizuki H; Motsinger-Reif A; Bettini C; Moroff S; Breen M Vet Comp Oncol; 2017 Sep; 15(3):829-839. PubMed ID: 27198171 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. Webster JD; Yuzbasiyan-Gurkan V; Thamm DH; Hamilton E; Kiupel M BMC Vet Res; 2008 Aug; 4():32. PubMed ID: 18700956 [TBL] [Abstract][Full Text] [Related]
26. Morphometrical approach for predicting regional lymph node micrometastatic load in canine mast cell tumours: preliminary results. Marconato L; Marchetti V; Francione D; Masserdotti C; Gregori M; Leotta R; Abramo F Vet Comp Oncol; 2008 Sep; 6(3):162-70. PubMed ID: 19178676 [TBL] [Abstract][Full Text] [Related]
27. Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices. Thompson JJ; Yager JA; Best SJ; Pearl DL; Coomber BL; Torres RN; Kiupel M; Foster RA Vet Pathol; 2011 Jan; 48(1):169-81. PubMed ID: 21160022 [TBL] [Abstract][Full Text] [Related]
28. Principles of treatment for mast cell tumors. Govier SM Clin Tech Small Anim Pract; 2003 May; 18(2):103-6. PubMed ID: 12831070 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of a modified proportional margins approach for surgical resection of mast cell tumors in dogs: 40 cases (2008-2012). Pratschke KM; Atherton MJ; Sillito JA; Lamm CG J Am Vet Med Assoc; 2013 Nov; 243(10):1436-41. PubMed ID: 24171373 [TBL] [Abstract][Full Text] [Related]
31. Mechanisms of pathogenicity in human MSH2 missense mutants. Ollila S; Dermadi Bebek D; Jiricny J; Nyström M Hum Mutat; 2008 Nov; 29(11):1355-63. PubMed ID: 18951462 [TBL] [Abstract][Full Text] [Related]
32. Mutation and methylation status of KIT and TP Vozdova M; Kubickova S; Fictum P; Cernohorska H; Fröhlich J; Rubes J Vet Comp Oncol; 2020 Sep; 18(3):438-444. PubMed ID: 31574575 [TBL] [Abstract][Full Text] [Related]
33. Analysis of risk factors for canine mast cell tumors based on the Kiupel and Patnaik grading system among dogs with skin tumors. Martins AL; Carvalho FF; Mesquita JR; Gärtner F; Amorim I Open Vet J; 2021; 11(4):619-634. PubMed ID: 35070857 [TBL] [Abstract][Full Text] [Related]
34. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558 [TBL] [Abstract][Full Text] [Related]
35. Surgically planned versus histologically measured lateral tumor margins for resection of cutaneous and subcutaneous mast cell tumors in dogs: 46 cases (2010-2013). Risselada M; Mathews KG; Griffith E J Am Vet Med Assoc; 2015 Jul; 247(2):184-9. PubMed ID: 26133218 [TBL] [Abstract][Full Text] [Related]
36. Zebrafish with mutations in mismatch repair genes develop neurofibromas and other tumors. Feitsma H; Kuiper RV; Korving J; Nijman IJ; Cuppen E Cancer Res; 2008 Jul; 68(13):5059-66. PubMed ID: 18593904 [TBL] [Abstract][Full Text] [Related]
37. Senescence-dependent MutS alpha dysfunction attenuates mismatch repair. Chang IY; Jin M; Yoon SP; Youn CK; Yoon Y; Moon SP; Hyun JW; Jun JY; You HJ Mol Cancer Res; 2008 Jun; 6(6):978-89. PubMed ID: 18567801 [TBL] [Abstract][Full Text] [Related]
39. Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours. Vozdova M; Kubickova S; Fictum P; Fröhlich J; Jelinek F; Rubes J Vet J; 2019 May; 247():71-74. PubMed ID: 30971355 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of the global DNA methylation in canine mast cell tumour samples by immunostaining of 5-methyl cytosine. Morimoto CY; Tedardi MV; da Fonseca IIM; Kimura KC; Sanches DS; Epiphanio TF; de Francisco Strefezzi R; Dagli MLZ Vet Comp Oncol; 2017 Sep; 15(3):1014-1018. PubMed ID: 27140659 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]